Edwards Lifesciences Corp (EW) Quote

WOOHOOOOOO EW$

Weeeeeeeeeeeee

WOOHOOOOOO

EW$

Big move up EW WOOHOOOOOO

3:1 Split for EW on June 1st. Adjust your parameters.

Have anyone see the earnings?
Is that true that beats estimations ??

$EW great article Edwards Lifesciences Corporation Nyse Ew Short Squeeze

Ugh. Off 5% on the day. (along with much of the health sector....)

EW up over 7% this AM with news out that Edwards and Boston Scientific have settled a patent dispute:
https://finance.yahoo.com/m/ed5c9955-43b5-3c4d-b71b-ac7ed1df50c4/edwards-lifesciences%27-stock.html

A 7+% gain on share price this AM. News says it might be an acquisition target.

https://www.barrons.com/articles/boston-scientific-edwards-lifesciences-may-tempt-j-j-1537575592?siteid=yhoof2&yptr=yahoo

It's trading well above its previous 52 week high.

Price/Share off 7% this AM.

Ouch!

It's been a while since I updated my EW position history. This histogram shows where it's been since the start in 2014 and updates what's happened since about a year ago:



I was lucky to cut overall risk exposure when I did as those funds were used to supplement other positions in a 10 stock portfolio. It's taken until just the last month or so for the stock to rise above that same price/share. Those opportunistic buys I made back under $100/share now look pretty good.

Value Line now gives EW a 3-5 year price target of between $160 and $245. It's still ranked A+ for financial strength with price growth persistence at 80 (5 to 100 range) and stock price stability of 45 (5 to 100 range).

Thanks. It will be fun to watch unfold and I have time to wait. Cash hasn't been earning anything for a very long time, so another price dip would make me smile. So would a price rise, but for a different reason.

The only time I'm not smiling is when the price/share goes flat!

Nice reply and lets hope that Value Line is correct. that target is a nice one.

Hi P, Re: Long term with EW.............

2014 was when I first added EW to my portfolio at around $36 (split adjusted). So, it's done well for me. Last Sept I reduced my overall holding in EW by around 50% because of it becoming overweight in that 10 stock portf. That was at around $116/sh.

About a month later it dropped back to $93 and I added back some shares. It continued down and I managed to add more shares at around $85/share.


(Stacked Bar Histogram: Red on bottom is cash in reserve, Green is the stock value)

It's again starting to throw off some cash for me with a sale of 10% of the shares at around $110/sh. I need an additional +10% added to the price before I'll again take some off the table.

This week's newest EW report from Value Line has raised its "Timeliness" rank to 2 with a 3-5 year "appreciation potential" target of $150 to $220/share. It also remains on their "Highest Growth Stocks" list (Page 39 of the Summary and Index section). It carries a VL Financial Strength rank of A+ (second highest).

It has a "Price Growth Persistence" rank of 80 (5 to 100 range) but carries a "Stock Price Stability" rank of 35 (5 to 100 range). So, it would appear it has a long term upward trend with hick-ups along the way. I've been trading the hick-ups while enjoying the long term growth.

I, too, am surprised it doesn't have much following here.

Can't wait to see where Edwards goes the next 12 months.

Surprised nobody is watching Edwards on this site. I invested back in 2013 and only wished I was smart enough to have bought more in the last year. I see EW eventually back to the 120.00 area before the end of 2017.

5yr DCF imply Edwards Lifesciences $EW has 9% upside before earnings Wednesday:

DCF Analysis

Hi J99, Re: Drop in price...........

I sold some of my position at around $116, so couldn't resist adding about 12% more to the remaining share count this AM at 93.19. That's about a 20% discount from my latest sale.

Value Line dropped their "Timeliness" rank on the 14th of this month to "4" which is second lowest (looking out 12 months). Yesterday's selling binge was massive. So, since this is a long term holding, I'm happy to have the extra shares. It's nice to profitably trade around the core position.

Still think this is oversold. Best in class med device in a huge industry. Unfortunate drop on earnings that were in line.

Saturday News....

http://www.prnewswire.com/news-releases/edwards-sapien-xt-valve-meets-primary-endpoint-in-partner-ii-trial-300245045.html

Inst % Owned = 95%

Float = 214.11M

EPS = 2.30

EW DAY

SEE MY POSTS AT


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=121003349





EW is 1 of 2
I am following starting today.

Anybody following EW? Where are we heading now that the big lawsuit is settled. Seems to be a good settlement for EW and with some nice future royalties.

I'm out of this one for now. Glad you are enjoying the PPS jump. I haven't decided whether or when to re- enter. Good luck to you.

fantastic move this morning..........

best, jeff

not sure about that, EW has a 50/200ema crossover approaching, if it

breaks up thru $73 and closes above, my guess EW can almost run to $100

by this summer, I'll wait till the chart tells me otherwise...................good luck

Thanks for sharing. In the past, outperform is code for you should have taken some profits, the price of this stock is getting ready to drop.

Edwards Life Sciences u[graded this morning to Outperform by Wells Fargo

no price target but i notice a lot of insider sells lately from option exercise....

Thanks for sentiment. I like this company, but I just sold all of my shares yesterday. I'm not sure why a company with such great products doesn't translate into superior stock performance. I'm out for now. I may come back in at a lower price. I made a few bucks after being under water for too long. Got out while gettin' was good. GLTA.

looks like EW on a upward trajectory for now, maybe get to $100

Boom! Medtronic Corevalve early approval granted by the FDA. See ya Edwards.

This stock has been doing well in my portfolio. But, i don't see many new posts to this board. What is going on here?

Can you point out the interesting parts for you? I tried to find something interesting but found that I was more distracted by the CFO's ramblings than anything else.

Goldman-Sachs Global-Healthcare-Conference

Interesting comments made by EW

read here

I'm a new investor. What happened with knock-off?

Look at ICU Medicals FloTrac knockoff. This could hurt

TAVI: Mixed results for Edwards' Sapien valve in latest Partner analysis

https://www.massdevice.com/news/tavi-mixed-results-edwards-sapien-valve-latest-partner-analysis

Edwards Lifesciences (NYSE:EW) reported EPS of $0.58 in the third quarter of 2012, surpassing the Zacks Consensus Estimate by $0.02. Sales increased 8.5% to $447.9 million, in line with the preliminary result but lagged the original guidance of $465-$485 million. This was primarily due to lower-than-expected THV sales due to economic uncertainties in Europe, coverage issues for certain inoperable patients in US and later-than expected approval of Sapien in high-risk patients.

Given these headwinds, the company lowered its outlook for 2012. We prefer to avoid the stock and accordingly downgrade it to Underperform.

Edwards current trailing 12-month earnings multiple is 36.3. The stock is currently trading at 27.1x the 2013 EPS estimate of $3.21. Our target price is based on 24.6x our 2013 EPS estimate.

there is interest,we just keep to ourselves, ihub message boards

for penny fluffers.....................

best

well, time to buy EW???????????

EW, another guidance hit

Co issues downside guidance for Q3 (Sep), sees Q3 (Sep) revs of $448 mln vs. $476.56 mln Capital IQ Consensus Estimate. This represents a growth rate of approximately 9 percent, or 14 percent excluding the impact of foreign exchange. This compares to the Company's guidance of $465 million to $485 million provided during its second quarter earnings conference call on July 24, 2012. Transcatheter heart valve sales were below expectations for the third quarter, with global sales estimated at $124 million, including U.S. sales of $55 million. "In Europe, austerity measures tempered procedural volumes, resulting in underlying sales comparable to the same period a year ago. In the U.S., we are pleased with the overall progress of the launch, with training of commercial sites continuing as planned and procedural success rates remaining high. However, under the provisions of the National Coverage Decision, there was no reimbursement for inoperable patients without femoral access. A clinical protocol that would allow reimbursement for this sizable group of patients was expected earlier; it is now anticipated in the next several weeks. Additionally, due to the requirement that a full Heart Team be present for every procedure, summer vacations had a more pronounced effect.... Despite the third-quarter sales shortfall, we anticipate a strong rebound in the fourth quarter. The pending FDA approval to expand the indication to treat U.S. high-risk patients with SAPIEN, as well as the recent addition of our larger 29mm valve and a third delivery approach to our clinical trial, will make this therapy available to a considerably broader group of patients. Assuming this FDA approval happens early this quarter, for full-year 2012, we expect to achieve the low end of both our current global THV sales guidance of $550 million to $600 million, and our U.S. THV sales guidance of $240 million to $260 million. We remain enthusiastic about the potential of this transformative technology to improve the lives of many of the patients who suffer from severe aortic stenosis..."

I can't understand why there is no interest in this stock, I have made a great deal of money on this investment. Cutting edge and FDA approval. It will split again.

I believe that this is a likely split candidate once again. Watch the movement here shortly.

I purchase this one on the low point, it make good up and down movement.